DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
TMCI logo

Treace Medical Concepts, Inc. Stock Price

NasdaqGS:TMCI Community·US$305.7m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

TMCI Share Price Performance

US$4.60
-2.57 (-35.84%)
​
US$5.00
Fair Value
US$4.60
-2.57 (-35.84%)
8.0% undervalued intrinsic discount
US$5.00
Fair Value
Price US$4.60
AnalystConsensusTarget US$5.00
AnalystHighTarget US$7.00
AnalystLowTarget US$4.50
Sun, 9 Aug 26
Fair ValueUS$5.00
Share Pricen/a

TMCI Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$5 8.0% undervalued intrinsic discount

Minimally Invasive Bunion Solutions Will Broaden Market Penetration

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$7 34.3% undervalued intrinsic discount

Aging Population And Obesity Will Transform Foot Surgery

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$4.5 2.2% overvalued intrinsic discount

Elective Bunion Procedure Deferrals Will Pressure Margins Yet Long-Term Demand Will Ultimately Endure

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
TMCI logo
Treace Medical Concepts
2.2% overvalued intrinsic discount

Elective Bunion Procedure Deferrals Will Pressure Margins Yet Long-Term Demand Will Ultimately Endure

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 23 Aug
Read Narrative
TMCI logo
Treace Medical Concepts
8.0% undervalued intrinsic discount

Minimally Invasive Bunion Solutions Will Broaden Market Penetration

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 9 Aug
Read Narrative
TMCI logo
Treace Medical Concepts
34.3% undervalued intrinsic discount

Aging Population And Obesity Will Transform Foot Surgery

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 22 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
TMCI logo

TMCI: Index Changes And Muted 2026 Outlook Will Shape Future Returns

Fair Value: US$4.5 2.2% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
TMCI logo

TMCI: Index Shifts And 2026 Outlook Will Shape Future Share Appeal

Fair Value: US$5 8.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
TMCI logo

TMCI: 2026 Foot Fusion Launches Will Support Long-Term Upside Potential

Fair Value: US$7 34.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Excellent balance sheet and fair value.

2 Risks
1 Reward
View Full Analysis

Treace Medical Concepts, Inc. Key Details

US$205.3m

Revenue

US$42.2m

Cost of Revenue

US$163.1m

Gross Profit

US$222.6m

Other Expenses

-US$59.5m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.92
79.45%
-28.99%
87.9%
View Full Analysis

About TMCI

Founded
2013
Employees
450
CEO
John Treace
WebsiteView website
www.treace.com

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Recent TMCI News & Updates

User avatar
Narrative Update • Aug 23

TMCI: Index Changes And Muted 2026 Outlook Will Shape Future Returns

Treace Medical Concepts' analyst price target has shifted to $4 from $2, with analysts pointing to updated fair value estimates and refreshed assumptions on growth, profitability and future P/E levels as key drivers of the change. What’s in the News for Treace Medical Concepts Treace Medical Concepts raised full year 2026 revenue guidance to a range of $204 million to $212 million, compared with previous guidance of $202 million to $212 million.
Analysis Article • Aug 12

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50

Treace Medical Concepts, Inc. ( NASDAQ:TMCI ) just released its second-quarter report and things are looking bullish...

Recent updates

No updates

Treace Medical Concepts, Inc. Competitors

BBNX logo

Beta Bionics

Symbol: NasdaqGM:BBNX
Market cap: US$897.5m
INMD logo

InMode

Symbol: NasdaqGS:INMD
Market cap: US$859.9m
SIBN logo

SI-BONE

Symbol: NasdaqGM:SIBN
Market cap: US$852.4m
HSTM logo

HealthStream

Symbol: NasdaqGS:HSTM
Market cap: US$849.4m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide